More specifically being granted insurance eligibility.
Is it because no evidence of an overall survival benefit has been established?
Has anyone read any information as to when any country,,,including the USA,,,is close to a approval.
Any published studies or even guesstimates as to progression free survival benefit,,,or overall survival benefit,,,or PCa specific death benefit??
In Germany most health insurance companies will pay for a PSMA PET/CT and a Lu177 treatment. It is not approved but offered by most nuclear medicine clinics, so the insurance companies have no good reason to object to cover the costs I guess.
The clinics produce the drug themselves or purchase it from a clinic which has the facility to do that. So they do not need big pharma for that. I assume the situation is similar in Australia.
I believe it's coming.
Where are you located? My husband is on the wait list for the trial at Weill Cornell in NYC - (a place to open up Sept/Oct) and according to the paperwork we completed our insurance will cover it. . . .
It won't be approved in the US until after the results of the VISION trial are analyzed, which is currently set for August 2020
In the Melbourne area there are 18 places where you can get a PSMA PET/CT done:
There is evidence for progression free and overall survival. But but not large randomised cohort studies. So public health systems internationally won't pay for it because it is not proved beyond reasonable doubt; too late for some of us. Privately you need to front up with $. Painful. R
German clinics and Lu-177
Lu-177 or Cabazitaxel
Lu-177 and Actinium 225 
Lu-177
